American Society of Hematology

Figure 1.

$Figure 1. Progression-free survival. (A) Progression-free (median, 20.4 months; solid line) and overall survival (dashed line) of patients with relapsed/refractory MCL from the time of initiation of rituximab plus thalidomide. (B) Progression-free survival after rituximab plus thalidomide (median, 20.4 months; solid line) was significantly longer compared with progression-free survival after the previous line of chemotherapy (median, 12.7 months; dashed line) (P = .027). (C) Progression-free survival (PFS) of patients with MCL achieving a CR after rituximab plus thalidomide (▪) compared with PFS after the previous line of chemotherapy (▦).$

Progression-free survival. (A) Progression-free (median, 20.4 months; solid line) and overall survival (dashed line) of patients with relapsed/refractory MCL from the time of initiation of rituximab plus thalidomide. (B) Progression-free survival after rituximab plus thalidomide (median, 20.4 months; solid line) was significantly longer compared with progression-free survival after the previous line of chemotherapy (median, 12.7 months; dashed line) (P = .027). (C) Progression-free survival (PFS) of patients with MCL achieving a CR after rituximab plus thalidomide (▪) compared with PFS after the previous line of chemotherapy (▦).

This Feature Is Available To Subscribers Only